Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DSM-V Revisions Could Open - Or Close - Opportunities For Drug Industry

Executive Summary

Drug firms with a major stake in neurologic and psychiatric drug development are closely monitoring the psychiatric profession as it goes through its once-a-generation revamp of the Diagnostic and Statistical Manual of Mental Disorders

You may also be interested in...



A New Dawn For Female Sex Dysfunction Drugs? FDA Meeting Cheers Sponsors

Experts convened by FDA to discuss female sexual dysfunction disorders, including problems with desire and arousal, settle on endpoints contrary to new DSM, but are in line with trials of Sprout’s flibanserin, the leading drug in development.

APA Takeaways: Former Sanofi Exec Reflects On DSM-5, Eroom’s Law And More

The recent American Psychiatric Association annual meeting featured a lecture on drug development by Sanofi’s former head of CNS development Robert Lenox. In a post-meeting interview, he weighs in on the highs and lows of psychiatric drug development, as well as the newly released fifth edition of the Diagnostic and Statistical Manual of Mental Disorders.

On A Revenue Roll, Shire Takes Specialist Tactics To “Primary Care” Markets

Shire targets specialist segments of vast primary care populations, with focus on areas of unmet need.

Related Content

Topics

UsernamePublicRestriction

Register

PS051969

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel